A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-26 / J Transl Med 2019 11;17(1):391Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-25 / J Immunol Res 2019;2019:9631515Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-755Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2019-11-14 / Front Oncol 2019;9:1169Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist
/in Hyperthermia, International Publications /von 2019-11-01 / Front Oncol 2019;9:1012Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo
/in Breast Cancer, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-11-01 / Int J Cancer 2020 01;146(2):531-541Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-11-01 / Am J Cancer Res 2019;9(11):2456-2468
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de